达比加群酯的研究进展

Progress in Research on Dabigatran Etexilat

达比加群酯是新型的口服直接凝血酶抑制剂,具有强效抗凝、出血风险低、无需特殊监测、药物相互作用少等优点,目前已成为临床研究的热点。该文综述了近年来相关的作用机制、药代动力学、临床应用等方面的研究,为达比加群酯的后续研究提供参考。

Dabigatran etexilate is a novel direct oral thrombin inhibitor. The drug has a strong anticoagulant feature, low risk of bleeding, no need for special monitoring, few drug interactions and other advantages and become a hot spot in clinical research. In this paper, the mechanism of action, pharmacokinetics, clinical application and other aspects are reviewed to provide reference for the further research of dabigatran etexilate.